Loading...
Market
Story
Incyte's Tafasitamab Shows Positive Results in Lymphoma Study
Aug 15, 2024, 08:36 PM
Incyte has announced positive topline results from a pivotal study of its blood cancer drug, Tafasitamab (Monjuvi®), in patients with relapsed or refractory follicular lymphoma. This development marks a significant advancement in the treatment of this type of lymphoma, which is often difficult to manage. The study's success adds to Incyte's growing portfolio of post-transplant drugs, enhancing its position in the oncology market.
View original story
Similar markets
Niktimvo • 25%
Jakafi • 25%
Pemazyre • 25%
Other • 25%
Less than 10% • 25%
10% to 19% • 25%
20% to 29% • 25%
30% or more • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10%-20% • 25%
20%-30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 19% • 25%
20% to 29% • 25%
30% or more • 25%
Less than 20% • 25%
20% to 40% • 25%
41% to 60% • 25%
More than 60% • 25%
0-10% • 25%
10-20% • 25%
20-30% • 25%
30% or more • 25%
0-10% • 25%
11-20% • 25%
21-30% • 25%
31% or more • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
More than 20% • 25%